Literature DB >> 33313984

Application study of the EQ-5D-5L in oncology: linking self-reported quality of life of patients with advanced or metastatic colorectal cancer to clinical data from a German tumor registry.

Kathrin Borchert1, Christian Jacob2, Natalie Wetzel3, Martina Jänicke3, Egbert Eggers4, Annette Sauer5, Norbert Marschner6, Julia Altevers2, Thomas Mittendorf2, Wolfgang Greiner7.   

Abstract

BACKGROUND: The EQ-5D-5L questionnaire is used in oncology to generate health-related quality of life (HRQoL) weights and corresponding health states. The purpose was to explore the relationship between demographic and clinical characteristics and HRQoL among advanced or metastatic colorectal cancer (CRC) patients by linking clinical data of a German CRC registry to self-reported HRQoL measures from the EQ-5D-5L.
METHODS: The study sample included patients with advanced or metastatic CRC currently recruited in the German Tumor Registry Colorectal Cancer. The EQ-5D-5L was administered once to patients who were at the start or at later stages of palliative treatment. Data on comorbidities, disease-specific health states, symptoms, and treatment status were drawn from the registry. Multivariate regression analyses were performed to explore the impact of patient and disease characteristics on HRQoL.
RESULTS: In total, n = 433 questionnaires were included in the data analysis. Mean age of patients was 66.3 years and 61.2% were male. The mean EQ-5D-5L utility score was 0.82 and the mean EQ-5D-5L VAS score was 62.05. The regression analyses revealed that none of the demographic characteristics and few of the clinical characteristics, such as fatigue and pain, had a significant impact on the HRQoL.
CONCLUSIONS: The study demonstrated a reduced HRQoL of patients with advanced or metastatic CRC when compared to the general population. The symptoms fatigue and pain negatively affected the HRQoL, whereas other characteristics such as age, gender, and comorbidities did not have a significant impact on HRQoL.

Entities:  

Keywords:  Colorectal cancer; Data linkage; EQ-5D-5L; Patient reported outcomes; Quality of life; Tumor registry

Year:  2020        PMID: 33313984     DOI: 10.1186/s13561-020-00297-6

Source DB:  PubMed          Journal:  Health Econ Rev        ISSN: 2191-1991


  6 in total

Review 1.  Is the EQ-5D suitable for use in oncology? An overview of the literature and recent developments.

Authors:  Matthias Schwenkglenks; Klazien Matter-Walstra
Journal:  Expert Rev Pharmacoecon Outcomes Res       Date:  2016-02-18       Impact factor: 2.217

2.  The quality of life questionnaire EQ-5D-5L: psychometric properties and normative values for the general German population.

Authors:  Andreas Hinz; Thomas Kohlmann; Yve Stöbel-Richter; Markus Zenger; Elmar Brähler
Journal:  Qual Life Res       Date:  2013-08-07       Impact factor: 4.147

3.  Palliative treatment of colorectal cancer in Germany: cost of care and quality of life.

Authors:  Martin Emmert; Katharina Pohl-Dernick; Axel Wein; Frank Dörje; Susanne Merkel; Frank Boxberger; Gudrun Männlein; Robert Joost; Hans-Detlev Harich; Roland Thiemann; Christof Lamberti; Markus F Neurath; Werner Hohenberger; Oliver Schöffski
Journal:  Eur J Health Econ       Date:  2012-06-12

4.  Quality of life in rectal cancer patients: a four-year prospective study.

Authors:  Jutta Engel; Jacqueline Kerr; Anne Schlesinger-Raab; Renate Eckel; Hansjörg Sauer; Dieter Hölzel
Journal:  Ann Surg       Date:  2003-08       Impact factor: 12.969

5.  Oxaliplatin-based first-line chemotherapy is associated with improved overall survival compared to first-line treatment with irinotecan-based chemotherapy in patients with metastatic colorectal cancer - Results from a prospective cohort study.

Authors:  Norbert Marschner; Dirk Arnold; Erik Engel; Ulrich Hutzschenreuter; Jacqueline Rauh; Werner Freier; Holger Hartmann; Melanie Frank; Martina Jänicke
Journal:  Clin Epidemiol       Date:  2015-04-20       Impact factor: 4.790

6.  German Value Set for the EQ-5D-5L.

Authors:  Kristina Ludwig; J-Matthias Graf von der Schulenburg; Wolfgang Greiner
Journal:  Pharmacoeconomics       Date:  2018-06       Impact factor: 4.981

  6 in total
  1 in total

1.  Quality of life of patients with hematological malignancies and factors affecting health state utility values.

Authors:  Keiichi Osaki; Shinichiro Morishita; Suzuho Takami; Yuki Sakai; Akiho Kamimura; Atsushi Shindo; Eri Kawata
Journal:  Support Care Cancer       Date:  2022-03-12       Impact factor: 3.603

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.